SOLICITATION NOTICE
B -- HPV Genotyping
- Notice Date
- 8/2/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100143-MM
- Archive Date
- 8/27/2010
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
(marinome@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis HPV genotyping of microdissected cervical biopsy specimens from DDL Diagnostic Laboratory B.V., Fonteynenburghlaan 7, 2275 CX Voorburg, Netherlands. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-1(b)(2) and 13.501-(a)(1) using simplified acquisition procedures for commercial acquisitions. The North American Industry Classification System code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Base year - 12 months plus one (1) Option year -12 months Research over the past 20 years has identified human papillomaviruses (HPV) as the necessary cause of cervical cancer. About 13-15 carcinogenic types may cause cancer. HPV infections are very common among sexually active women and only a small subset progresses to cervical cancer. Multiple HPV infections occur frequently, and it is hard to discriminate a causal type, i.e. a type responsible for a lesion, from a passenger type, i.e. a type that is only found in a transient infection but does not cause precancer or cancer. This is complicated by the fact that the cervix may harbor multiple lesions of different severity at the same time, caused by the same or different HPV genotypes. The Division of Cancer Epidemiology and Genetics is conducting the NCI Biopsy Study to address the complexity of cervical disease by taking multiple biopsies from different abnormal lesions on the cervix. Even individual biopsies may harbor multiple types; therefore it is important to analyze HPV infection on the microscopic level using laser capture microdissected tissue specimens. All sensitive HPV detection methods suited for paraffin embedded tissues require target amplification via PCR. Thus, there is a high risk of contamination if samples are not processed according to highest standards. The contractor shall perform human papillomavirus genotyping from biopsy samples collected in the NCI Biopsy Study. The objectives are to identify causal types in complex cervical disease with multiple lesions and multiple HPV genotype infections to understand the progression from infection to precancer. Study enrollment is ongoing; in the first 12 month period, 230 biopsy samples will be processed with an additional 145 biopsy samples processed during the 12-month option period. DDL Diagnostic Laboratory is the central World Health Organization (WHO) reference laboratory for HPV genotyping. It is the only known commercial provider of reliable tissue-based genotyping using microdissection and subsequent detection of 28 different HPV genotypes. In addition, DDL Diagnostic Laboratory is the only known source capable of providing tissue-based HPV genotyping according to the following specification, required to achieve the goals of the NCI Biopsy Study: (1) Identification and microdissection of cervical lesions from paraffin-embedded tissue sections. (2) Processing and DNA purification at highest standards to avoid contamination. (3) Reliable genotyping using a PCR system with short target sequences to avoid problems with DNA fragmentation in paraffin-embedded tissues. (4) Ability to analyze hundreds of biopsies at high throughput and consistently high quality. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 12, 2010. For further information, please contact Melissa Marino, Contract Specialist via electronic mail at marinome@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100143-MM on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100143-MM/listing.html)
- Record
- SN02225758-W 20100804/100802235257-da396b97ad6eb7ec4f7d511f85d9e325 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |